Word: costes
(lookup in dictionary)
(lookup stats)
Dates: during 2000-2009
Sort By: most recent first
(reverse)
...paper is being rolled out in the German capital on Nov. 16 with a target circulation of 5,000 in the first six months. After Berlin, the publishers are planning to expand distribution to other German cities and European capitals. The daily paper will cost $2.70 (€1.80), but students will pay just $1.80 (€1.20), about the same price as one of Germany's mainstream newspapers, like Süddeutsche. The founders of Niiu say that readers will end up saving money in the long run because they won't have to buy different newspapers anymore. (Read "The State...
...portfolio of climate-change activities," says Steve Hamburg, chief scientist for the Environmental Defense Fund and a corresponding author on the second Science paper. "But we have to make sure we incentivize the right way, or we could end up with perverse outcomes." (Watch a video about the environmental cost of biofuel in Indonesia...
...believes in the higher risk and returns of equities, but his stock investments are widely diversified, including international holdings, and are mostly in low-cost index funds...
...there's a dilemma: policymakers want to foster cost-saving competition without killing the financial incentives that have put the U.S. biotechnology industry at the vanguard of medical science and without stifling the development of even more drugs that could save lives and eliminate suffering. Finding that equilibrium goes to the question of how long biotech firms should be guaranteed exclusivity, outside the protection of their patents, before copycats can begin using the data they have developed...
...groups. One, called RetireSafe, receives regular infusions of "general operating support" from Pfizer and operates out of a small Washington law-firm office. It has been blitzing Capitol Hill with letters arguing that guaranteeing biologics makers fewer than 12 years of exclusivity in the use of their data could cost lives. The other group, the Alliance of Aging Research, is also run by the drug industry. Its chairman is the managing partner of Foxkiser, a drug-company consultant, and its vice chairman is with Novartis...